Genmab exceeds revenue expectations in first months of year - guidance maintained
Genmab’s revenue growth is primarily driven by strong Darzalex sales. The company keeps the outlook unchanged.
Biotech company Genmab has reported strong sales growth for the first three months of the year, beating analyst expectations, but the company is maintaining its full-year guidance for now.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
